SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
American Journal of Hospice and Palliative Medicine®
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Davis, M. P.
Right arrow Articles by Lycan, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davis, M. P.
Right arrow Articles by Lycan, J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*AMITRIPTYLINE
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Mirtazepine: Heir apparent to amitriptyline?

Mellar P. Davis, MD, FCCP

Harry R. Horvitz Center for Palliative Medicine, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio

E. Duke Dickerson, MSc, PhD

Oxford International Centre for Palliative Care, Health Sciences and Systems, Columbus, Ohio

Marco Pappagallo, MD

New York University, New York, New York

Costantino Benedetti, MD

Cancer Pain and Palliative Medicine, Ohio State University Arthur G. James Cancer Hospital, Columbus, Ohio

Phyllis A. Grauer, RPh

Education, Academics, Industry, Medicine and Society (AIMS), Cleveland, Ohio

Jeff Lycan, RN

Ohio Hospice and Palliative Care Organization, Columbus, Ohio

"What’s new in therapeutics?" will examine and evaluate drugs that may have a place in hospice, palliative, and long-term care. Mirtazepine will be examined and evaluated. Mirtazepine is a potential alternative anti-depressant with multiple additional benefits. It is an atypical anti-depressant, which has both noradrenergic and specific serotonergic receptor antagonism (NaSSa), and a unique pharmacological profile. Mirtazepine appears to be a "designer drug" for palliative medicine with a number of benefits, but cost may be a drawback.

Key Words: anti-depressants • Mirtazepine • noradrenergic and specific serotonergic receptor antagonism (NaSSa) • palliative care • pharmacotherapy • portmanteau • selective serotonin reuptake inhibitor (SSRI)

American Journal of Hospice and Palliative Medicine®, Vol. 18, No. 1, 42-46 (2001)
DOI: 10.1177/104990910101800111
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 BMJ Case ReportsHome page
B. Hannon, P. Fitzgerald, and M. Murphy
Treatment of depression as part of end-of-life care
BMJ Case Reports, November 20, 2008; 2008(nov12_1): bcr0820080841 - bcr0820080841.
[Abstract] [Full Text]


Advertisement